Hydrocortison Tiofarma (Hydrocortisone)

Hydrocortison Tiofarma is prescribed for several medical conditions that involve cortisol deficiency or excessive inflammation.

• Replacement therapy for primary or secondary adrenal insufficiency.
• Management of acute or chronic inflammatory disorders such as dermatitis, arthritis, or ulcerative colitis.
• Treatment of severe allergic reactions, including anaphylaxis adjunct therapy.
• Control of autoimmune conditions where immune suppression is required.

• Hydrocortison Tiofarma delivers hydrocortisone, which mimics the natural glucocorticoid cortisol. The compound binds to intracellular glucocorticoid receptors, forming a hormone‑receptor complex that translocates to the nucleus. This complex interacts with glucocorticoid response elements on DNA, modulating transcription of anti‑inflammatory proteins and suppressing pro‑inflammatory cytokines. The net effect reduces inflammation, limits immune cell activation, and restores deficient glucocorticoid activity in adrenal insufficiency.

Like other systemic corticosteroids, Hydrocortison Tiofarma may cause a range of adverse reactions, varying in frequency and severity.

Common

• Mild gastrointestinal discomfort or nausea.
• Transient increase in blood glucose levels.
• Fluid retention leading to mild swelling.
• Mood changes such as irritability or insomnia.

Serious

• Signs of infection due to immune suppression.
• Severe hypertension or electrolyte imbalance.
• Adrenal crisis on abrupt discontinuation.

Healthcare providers should evaluate several factors before initiating Hydrocortison Tiofarma therapy.

• Assess for active infections or uncontrolled diabetes before use.
• Monitor blood pressure, blood glucose, and electrolyte levels regularly.
• Use the lowest effective dose for the shortest duration possible.
• Consider alternative therapies in patients with known hypersensitivity to corticosteroids.
• Counsel patients on the risk of adrenal suppression with prolonged treatment.
• Avoid use during pregnancy or lactation unless benefits outweigh risks (consult physician).

Hydrocortison Tiofarma can interact with other medicines, affecting its efficacy or safety profile.

Avoid

• Concurrent use with potent CYP3A4 inducers (e.g., rifampin, phenytoin) may reduce hydrocortisone levels.
• Combining with systemic immunosuppressants (e.g., cyclosporine) can increase infection risk.
• Co‑administration with non‑steroidal anti‑inflammatory drugs (NSAIDs) may raise the chance of gastrointestinal bleeding.

Use with caution

• Concurrent use with anticoagulants (e.g., warfarin) may enhance anticoagulant effect.
• Combining with antidiabetic agents may require dose adjustments due to altered glucose control.
• Use with vaccines, especially live attenuated, should be carefully considered.